CACO-0051 PATENT

WHAT IS CLAIMED IS:

1. A method of preparing a substantially RNA-free cellular component, comprising culturing cells producing the cellular component in a medium and lysing said cells to produce a cell lysate, wherein said cell lysate contains said cellular component and sufficient RNase activity to degrade substantially all of the RNA molecules present in said cell lysate.

2. The method of claim 1, wherein the RNase is produced by said cells producing the cellular component.

3. The method of claim 1, wherein the RNase is produced by said cells in the medium other than said cells producing the cellular component.

- 4. A method of preparing a substantially RNA-free cellular component, comprising culturing and lysing cells producing the cellular component and cells producing an RNase in an amount sufficient to degrade substantially all of the RNA present in the preparation.
- 5. The method of claim 4, wherein the cells producing the cellular component also produce the RNase.
- 6. The method of claim 4, wherein the cellular component and the RNase are not produced by the same cells.
- 7. The method of claim 1 or 4, wherein said cellular component is one of a recombinant DNA, a recombinant protein, and a recombinant carbohydrate.
- 8. The method of claim 1 or 4, wherein the gene encoding said RNase is integrated into the genome of the cell producing the RNase.
- 9. The method of claim 1 or 4, wherein said RNase is non-specific.
- , 10. The method of claim 9, wherein said non-specific RNase is RNase A, RNase M or RNase I.
- 11. The method of claim 1 or 4, wherein said cell producing said RNase produces said RNase in a regulated manner.


SUB

10

Ju B

ShB 21

July F4



- 13. The method of claim 11, wherein said RNase produced in said regulated manner is inducibly produced by said cell producing said RNase.
- 5 14. The method of claim 11, wherein said RNase produced in said regulated manner is constitutively produced by said cell producing said RNase.
 - 15. The method of claim 11, wherein said RNase produced in said regulated manner is secreted out of the cytoplasm of the cell producing said RNase.
- 16. The method of claim 15, wherein said RNase is secreted into the periplasm of the cell producing-the RNase.
 - 17. The method of claim 16, wherein the cell is contained in a medium and said RNase is secreted out of the cell into said medium.
 - 18. The method of claim 11, said RNase being a non-specific RNase.
- 19. A host cell that produces a recombinant DNA, a recombinant protein, or a recombinant carbohydrate and also produces an RNase in a regulated manner.
 - 20. The host cell of claim 19, wherein said RNase produced in said regulated manner is overproduced.
 - 21. The host cell of claim 19, wherein said RNase produced in said regulated manner is inducibly produced.
- 20 22. The host cell of claim 19, wherein said RNase produced in said regulated manner is constitutively produced.
 - 23. The host cell of claim 19, wherein said RNase produced in said regulated manner is secreted out of the host cell cytoplasm.
- 24. The host cell of claim 23, wherein said RNase is secreted into the host cell periplasm.

CACO-0051 PATENT

25. The host cell of claim 23, wherein when the host cell is contained in a medium, said RNase is secreted out of the host cell into said medium.

- 26. The host cell of claim 19, said RNase being a non-specific RNase.
- 27. A composition comprising a host cell that produces a recombinant DNA, a recombinant protein, or a recombinant carbohydrate and a host cell that produces an RNase in a regulated manner.
 - 28. The composition of claim\27, wherein said RNase produced in said regulated manner is overproduced.
- 29. The composition of claim 27, wherein said RNase produced in said regulated manner is inducibly produced.
 - 30. The composition of claim 27, wherein said RNase produced in said regulated manner is constitutively produced.
 - 31. The composition of claim 27, wherein said RNase produced in said regulated manner is secreted out of the host cell cytoplasm.
- 15 32. The composition of claim 31, wherein said RNase is secreted into the host cell periplasm.
 - 33. The composition of claim 31, wherein when the host cell is contained in a medium, said RNase is secreted out of the host cell into said medium.
- 34. A pharmaceutical composition comprising a cellular component that is substantially 20 RNA-free, in a pharmaceutically acceptable carrier.
 - 35. A pharmaceutical composition comprising a cellular component that is substantially RNA-free obtainable by the method of claim 1 or claim 4, in a pharmaceutically acceptable carrier.